These results have important implications in cancer immunotherapy and the treatment of autoimmune diseases, as TGFβ-insensitive cells would be ideal candidates for the adopted therapy of cancer and priority targets for the therapy of autoimmunity and graft immunity. This evidence concerns the gene TGFB1 and cancer.